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Surgical treatment for angina pectoris was first proposed in 1899. Decades of experimental surgery for coronary artery disease finally led to the
introduction of coronary artery bypass grafting (CABG) in 1964.Now that we are approaching 50 years of CABGexperience, it is appropriate to
summarize the advancement of CABG into a procedure that is safe and efficient. This review provides a historical recapitulation of experimental
surgery, theevolutionof the surgical techniquesand theutilizationofCABG.Furthermore,dataoncontemporaryclinical outcomesarediscussed.
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Introduction
In 1899, Francois Franck proffered the first surgical treatment for
angina pectoris; he believed that ligation of sympathetic pain pathways
would result in relief of angina.1 Several decades later, a number of
groups started performing surgical sympathectomy that indeed
resulted in relief of angina, yet this was found to be inconsistent.
Moreover, mortality remained high during follow-up, and although
patients no longer experienced symptoms, the consequences of the
underlying coronary artery disease (CAD) continued.
To specifically address reduced myocardial perfusion, several ex-
perimental surgical techniques were designed to supply external
blood to the myocardium (Figure 1). Thorel in 1903 suggested that
pericardial adhesions to the myocardium could provide blood to is-
chaemic areas,2 which was confirmed in 1932 by Moritz et al.3 Peri-
cardial abrasion was performed either mechanically or with the use
of irritants (e.g. beef bone, aleuronat, talc) to initiate formation of
adhesions.4,5 Simultaneously, numerous tissues were used as ‘collat-
erals’ and sutured to the ventricle:1,6 in 1935, Beck used the pectoral
muscle,7 in 1936 O’Shaugnessy the great omentum,8 in 1937 Lezius
the lung,9 and in 1954 Key used a pedicle of jejunum.10
The internalmammaryartery (IMA) formedan areaof interest early
on, particularly after the report of Fieschi in 1939. He ligated the right
IMA at the second intercostal space to increase blood flow to the
coronary circuit through smaller anastomotic collaterals from the
IMA bed.4 Although angina was significantly reduced in up to 95% of
patients,11 a study with sham controls proved no benefit of ligating
the IMA.12 It was not until the work by Arthur Vineberg in 1946 that
the use of the IMAwas starting to show promising results.13 He skele-
tonized the left IMA and tunneled the artery next to the left anterior
descending (LAD) coronary artery—without using any anasto-
mosis—in a tract in the ventricular wall he made with a tonsil-type in-
strument. Remarkably, in 71% of dogs with ischaemic heart disease
spontaneous anastomosis developed;14 probably because dogs have
greater capacity to form collaterals.15 Beck in 1946 moved away
from the IMA and focused on the coronary sinus; in dogs he used a
segment of the carotid artery as a graft between the descending
aorta and coronary sinus creating a systemic-cardiac arteriovenous
fistula,16 which for obvious reasons failed to help patients. Prophetic-
ally,Murray in1954 suggested that onewouldneeddirect anastomosis
to the LAD to provide the best results, and like Beck he also favoured
the carotid artery.17 Thereafter, Goetz and colleagues in 1960 per-
formed an IMA-right coronary artery anastomosis using a nonsuture
technique with a tantalum ring as a connector device.18
One of the most crucial developments was that of coronary angi-
ography byMason Sones;19 he demonstrated the formation of collat-
erals after the Vineberg operation, but, more importantly, was able
to evaluate native coronary arteries and identify lesions that required
* Corresponding author. Tel: +31 10 70 35784, Fax: +31 1070 33993, Email: a.kappetein@erasmusmc.nl
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2013. For permissions please email: journals.permissions@oup.com
European Heart Journal (2013) 34, 2862–2872
doi:10.1093/eurheartj/eht330
targeted therapy. Coronary angiography was quickly considered to
be mandatory to select patients and plan the procedure. Its use
during follow-up resulted in the recommendation to perform revas-
cularizationoncoronaryarterieswith.75%stenosis toensuregood
patency rates.20
These advancements finally led to the ‘modern’ coronary artery
bypass grafting (CABG) procedure of the mid-1960s (Figure 2A).
Vasilii Kolesov is believed to have been the first to perform a
sutured anastomosis of an IMA to the LAD on February 25th,
1964.21 Later that year, on November 23rd, a team led by Michael
DeBakey performed a saphenous vein aorta-coronary bypass with
a continuous suture technique.22 Although not the first to perform
this operation, Rene´ Favaloro was the first to systematically
perform CABG with reproducible results.23 He is considered the
‘father’ of bypass surgery and is acknowledged for his tremendous
contribution in the field of surgical revascularization.20,24
From initial experiences
to the standard of care
Quickly it became clear that given the limited possibilities of medical
therapy at the time, surgical revascularization could be very beneficial
for patients with CAD. In a review of .10 000 CABG procedures
performed before 1971 at 16 selected centres, 70–95% of patients
had improved their symptomatic status and 60–70% became asymp-
tomatic.25 However, operative mortality was as high as 10% in some
large series.20,25 Skepticismwas additionally fueled by a perioperative
myocardial infarction (MI) rate of 15%.26 With growing experience,
the rate of mortality andMI reduced significantly,27 but still remained
high in some all-comers series; respectively 7 and 14%.28 Selection
of patients appeared of paramount importance, as mortality was sig-
nificantly higher in patients who suffered a recent MI with/without
severe left ventricular dysfunction,29,30 or who underwent concomi-
tant procedures.28
The controversial early data unmasked the need for comparative
effectiveness analyses of CABG and medical therapy in the form of
randomized clinical trials. While it was unquestionable that surgery
relieved angina, it remained unclear whether there would also be a
benefit in reducing long-termmortality and preventing future MI, es-
pecially since the introduction of b-blockers had in the meantime
optimized medical therapy. Several retrospective and prospective
(randomized) studieswereperformedbutwereunable to showa sig-
nificant survival benefit of CABG over optimal medical therapy in
patients with stable angina,31–34 with the exception of patients
with left main disease.35,36 However, these studies were heavily criti-
cized for their (i) selectionbias, (ii) useof historical controls, (iii) com-
parability of study groups and (iv) small sample size.37 The results
from three large trials formed the basis for clinical decision making:
the Veterans Administration (VA) Cooperative Study (n ¼ 686),38
theEuropeanCoronarySurgeryStudy (n ¼ 767)39 and theCoronary
Artery Surgery Study (n ¼ 780) (CASS).40 Although the individual
trials did not consistently show superiority of CABG over medical
therapy in terms of long-term survival, they provided much of the
Figure 1 Experimental surgery for coronary artery disease that preceded the introduction of coronary artery bypass grafting. Different surgical
methods have been applied: (A) ligation of the right internal mammary artery to increase blood flow to the coronary circuit through collaterals, (B)
pericardial abrasion with the use of irritants to form adhesions, and (C) suturing different tissues to the myocardium as collaterals.
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basis for a later meta-analysis of seven trials that reported a survival
benefit with CABG at 5 (OR ¼ 0.61, 95% CI 0.48–0.77), 7 (OR ¼
0.68, 95% CI 0.56–0.83) and 10 years (OR ¼ 0.83, 95% CI 0.70–
0.98) of follow-up.41 Besides the relief of symptoms, the benefits of
CABG now included an improved prognosis after which it evolved
as the standard of care for the treatment of CAD on the grounds
of evidence-based recommendations rather than expert opinion.
The costs involved with CABG procedures were criticized for its
possible impact on health care budgets. However, apart from
prolonging life, compared with medical therapy, CABG also signifi-
cantly improves the quality of life for at least up to 5 years.42,43 In
the MASS-II trial, angina-free survival at 5-year follow-up was 54.8%
for patients in the medical therapy group vs. 74.2% in the CABG
group (P, 0.001).44 Although initial hospitalization costs are
indeed higher for patients undergoing CABG, these are counterba-
lanced by the long-term benefits of the treatment. Compared with
other therapies, the benefit of CABG on quality-adjusted-life-years
proved favourable.45,46
Utilization of coronary artery
bypass grafting
After the successful introduction of CABG, the procedure remained
in a state of relative experimental therapy outside of a fewpioneering
centres.47–49 In the beginning of the 1970s, larger experiences were
published which resulted in a growing interest in surgical revascular-
ization. At one point, it was even anticipated to become the ‘most
frequently performed operation in America’.22
In the 1960s, .35% of total deaths per 100 000 population in the
USAwere the result of ischaemic heart disease,whichwas somewhat
lower in European countries (e.g. United Kingdom 29% and the
Figure 2 Timeline of developments that led to the first ‘modern’ coronary artery bypass grafting (A) and facilitated continuous improvements in
surgical technique and outcomes during the first 50 years (B).
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Netherlands25%).50 Theoption of surgical revascularizationwas a
long awaited solution for patients with CAD, and like any disruptive
technology was quickly adopted with widespread enthusiasm. The
annual number of CABG procedures in the USA increased rapidly
to 30 000–40 000 in 1974 and exceeded 60 000 in 1976.34,51 By
1976, it was estimated that already more than 300 000 patients
had undergone CABG.34 The annual rate continued to grow to
114 000 procedures/year in the USA alone by 1979.52
Andreas Gru¨ntzig introduced percutaneous coronary interven-
tion (PCI) in1978,53whichprovided analternative treatment strategy
for symptomatic CAD. Nevertheless, the annual CABG rate contin-
ued togrowto191 000CABGprocedures/year in 1983 in theUSA.54
When the indications for PCI quickly developed first for acute MI55
and later for stable single- and multivessel disease with the develop-
ment of bare-metal stents, PCI rates started to grow exponentially
and already by 1986 more than 133 000 PCIs were performed annu-
ally in the USA.56 Continuous technical advancements of PCI (e.g.
drug-eluting stents) and adjuvant medical therapy (e.g. P2Y12 recep-
tor antagonists) allowed a broader range of clinical scenarios to
be treated percutaneously. As a result, CABG more and more
became reserved for patients with complex lesions.
Despite the dramatic increase in PCI procedures during the
1990s,57 there was also an expansion of the number of CABG pro-
grams thereby increasing the absolute rate of CABG per popula-
tion.58,59 In an analysis of European countries, the annual rate of
CABG increased from 137 000 to 225 000 procedures/year
between 1992 and 2000.58 In the USA, there was also a constant in-
crease in the number of CABG procedures, although the age- and
gender-adjusted rate per 100 000 population finally leveled out at
100–150 procedures/year.59,60 Approaching the turn of the millen-
nium and a stage of market saturation, the utilization of CABG
started to decline. Community-based studies in Olmsted andWash-
ington State showed a significant shift in the PCI-to-CABG ratio;
while the increase in the number of revascularizations stagnated,
the number of PCIs continued to rise as the number of CABGs
declined.59,60 Through 2001–2008, the number of revascularization
procedures in theUSAhave declined from5569 to 4748 per 100 000
population due to a significant reduction of CABG (1742 to 1081;
P, 0.001) but not PCI (3827–3667; P ¼ 0.74).61 This has been pre-
dominantly the result of the absence of a survival benefit with CABG
in randomized trials performed during the 1990s and 2000s. Results
from theBARI trial showed that 71.0 and73.5%patientswerealive10
years after PCI and CABG, respectively (P ¼ 0.18), and survival free
of MI was comparable (63.9% vs. 63.6%, respectively; P ¼ 0.97).62 In
larger pooled analyses with 5-year follow-up, there were also no dif-
ferences in survival or the compositeof deathorMI.63,64More recent
results from the SYNTAX trial andASCERT study have contradicted
these findings and may initiate another shift in the PCI-to-CABG
ratios in favour of CABG.65,66
Over 50 years, the increase in the number of CABG procedures
has shown significant inter-country variation. Between 1985 and
2006, there was a 6% increase in CABG procedures in the USA,
while there was a staggering 915% increase in Germany
(Figure 3A).67,68 The average annual number of CABG procedures
per100 000 is 62.2 in contemporaryWesternpractice, but differs sig-
nificantly by country ranging from 29.3 to 135.4 procedures in Spain
and Belgium, respectively (462% variation) (Figure 3B).68 When
considering age-standardized death rates from ischaemic heart
disease, the ratioofCABGperdeath varies evenmore from0.17pro-
cedures/death in Hungary to 1.40 procedures/death in Germany
(817% variation) (Figure 3C). This variation may be the result of
a myriad of reasons, including, but not limited to: patient and/or
physician preferences, the number of centres performing CABG,
differences among private and public sectors, thresholds for revascu-
larization and import/export of patients to best practices in more
developed countries.
Research
A simple entry of ‘CABG OR coronary bypass’ in PubMed yields 59 732
publications in peer-reviewed journals through 1964–2012
(Figure 4). Over the past 10 years, this search results in consistently
2300–2500publications annually. Thebodyof evidenceoriginating
from this research has (i) produced a technical evolution of the pro-
cedure, (ii) focused on complications that are associatedwithCABG,
(iii) provided an estimate of the incidence in which these complica-
tions occur and (iv) identified predictors of short-and long-termout-
comes. These data have led to continuous quality improvements and
have been incorporated in clinical decision-making and guideline-
directed treatment recommendations.
An evolution of the technique
Myocardial protection
Initially, CABGwas almost exclusively performedwith the use of car-
diopulmonary bypass (CPB) and the anastomoses were performed
on the arrested heart. Myocardial protection during the period of
induced ischaemia was found to be of utmost importance as opera-
tivemyocardial injurywasdirectly resulting in left ventricular dysfunc-
tion, thereby impacting prognosis.69 The work by Follette, Buckberg
and colleagues in the 1970s demonstrated the deleterious effects of
induced ischaemia and reperfusion injury and triggered a whole new
field of research.70 Improved CPB techniques, advanced anaesthesia
techniques, shorter-operating times and more refined suturing all
contributed to reducing the amount of myocardial injury.71
However, the introduction of myocardial protection is believed to
be the single most important contribution to CABG.71 Operative
mortality and morbidity were significantly reduced in the early
1970s by using potassium cardioplegia to lower myocardial energy
demands during the ischaemic period (Figure 2B).72 In the 1980s,
advanced myocardial protection methods aimed at providing
oxygen, optimizing the metabolic rate, reducing calcium influx, re-
versing acidosis, avoiding edema and replenishing substrates.70
Over the years, two different types of cardioplegia have been ex-
tensively investigated; blood and crystalloid cardioplegia. Warm
blood cardioplegiamay have an advantage over crystalloid cardiople-
gia as it resembles the normal physiology, which could result in less
myocardial injury andbetter clinical outcomes.However, administra-
tion of blood cardioplegia is more complex than for crystalloid cardi-
oplegia: (i) it can be cold, normothermic, or warm, (ii) it can be
administered antegrade or retrograde and (iii) should it be given con-
tinuous or intermittent, and atwhat interval betweendoses? Crystal-
loid cardioplegia is less expensive and provides better intraoperative
visibility.73 The most recent meta-analysis summarized data from 36
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Figure 3 The utilization of coronary artery bypass grafting around the world. The increase in coronary artery bypass grafting procedures per
100 000 population has differed significantly between countries (A), as well as the number of coronary artery bypass grafting procedures that are
performed in contemporarypractice (2006) (B). Thesedifferences are independent of theprevalenceof ischaemic heart disease (C).Dataoriginated
from the Organization for Economic Co-operation and Development68 and from Rothlin.67 AUS, Australia; CAN, Canada; CZE, Czech Republic;
DNK, Denmark; FIN, Finland; FRA, France; DEU, Germany; HUN, Hungary; ISL, Iceland; IRL, Ireland; ITA, Italy; LUX, Luxembourg; NLD, Nether-
lands;NZL,NewZealand;NOR,Norway; POL, Poland; PRT, Portugal; ESP, Spain; SWE, Sweden;CHE, Switzerland;GBR,UK;USA,United States of
America.
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randomized trials and was unable to identify a clear advantage of one
cardioplegic over the other for endpoints of death (RR ¼ 0.95, 95%
CI 0.60–1.51), MI (RR ¼ 0.80, 95% CI 0.55–1.19), or low cardiac
output syndrome (RR ¼ 0.69, 95%CI 0.48–1.04).74 The debate con-
tinues and until large randomized trials show a particular benefit it
appears that surgeons should continue using their own preferred
strategy, in which they have experience and that allows proper myo-
cardial protection in their cases.
The clinical impact of other measures of myocardial protection
remain debated: whetherCPB flow should be non-pulsatile or pulsa-
tile to mimic the physiological blood flow,75 whether direct and
remote ischaemic preconditioning through a number of brief
periods of ischaemia proves to have a clinical benefit by increasing
the tolerance of the myocardium to sustain a large period of ischae-
mia,76 aswell as theuseofprophylacticoradjunctivepharmacological
agents to minimize ischaemia and/or reperfusion injury.77,78
Grafts
In the early yearsof coronary surgery, the saphenous vein graft (SVG)
was used in the majority of cases;28 in 1979 in the USA, it was used in
87% of CABG procedures.52 However, in 1978 FitzGibbon et al.79
demonstrated that venous bypass grafts fail early: 11% of 1400 vein
grafts were occluded at 2–3 weeks postoperatively. At 1 year,
failure rates of up to 20% have been reported,80,81 and only 60% of
SVGs are open at 10-year follow-up.82,83 This failure rate is particu-
larly influenced by graft thrombosis (early failure), intimal hyperplasia
(late failure) and atherosclerosis (late failure).84
Although the first ever CABG was performed using an IMA graft,
IMA grafting was only done in few centres. Favaloro et al. were
particularly interested in this technique, and by the end of 1967 had
already performed 248bilateral IMAgraft procedures.20 Throughout
the historyofCABG, theClevelandClinic has provided seminalwork
demonstrating data in favourof IMAgrafting.They reportedexcellent
graft patency and significantly better survival in patients receiving an
IMA graft to the LAD instead of SVGs only.85 Second, they demon-
strated for the first time that bilateral IMA grafting proved superior
to single IMA grafting in reducing rates of reoperation and long-term
mortality.86,87 The excellent patency of the IMA graft triggered a
search for additional arterial grafts to revascularize non-LAD myo-
cardial territories. Experimental surgeries were performed using
the splenic artery,88 subscapular artery,89 intercostal artery,90 lateral
femoral circumflex artery,91 inferior mesenteric artery92 and ulnar
artery.93 In 1978, the use of Gore-Tex grafts was suggested,94 but
because of the high thrombogenicity and disappointing patency
rates this technique was quickly abandoned. The most promising ar-
terial conduits besides the IMA were the right gastroepiploic artery
(GEA),95 inferior epigastric artery (IEA)96 and radial artery.97
TheGEA and IEAwere introduced in 1987 and 1990, respectively,
and showed goodpatency results in several studies.98However, their
use has never been fully integrated into clinical practice because of a
number of technical issues, including the need for an additional lapar-
otomy, limited graft length, variation in size and small distal diameter.
Differences in biological characteristics when compared with the
IMA graftmake them also less suitable.99,100Data fromCABGproce-
dures performed in 1992 in the UK showed that in only 3% of cases
one of these grafts was usedmainly when the IMA or SVGswere not
available.101
The radial artery is the best and most commonly used arterial al-
ternative (or addition) to the right IMA graft. Its use was first investi-
gated byCarpentier in 1971,97 butwas discarded after high early graft
occlusion rates of 30% were reported.71 The unexpected finding of
patent grafts after .15 years renewed the interest in the radial
Figure 4 Peer-reviewed articles published since the introduction of coronary artery bypass grafting. The searchwas performed using an entry of
‘CABG OR coronary bypass’ in PubMed.
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artery during the early 1990s,102 although concerns remained with
regard to its susceptibility for spasm and intimal hyperplasia.103,104
Refined operative techniques aim at minimizing endothelial damage
and adjunctive medical therapy are applied to reduce vasoreactivity.
As a result, 5-year patency rates of.90%have been reported,105 but
are strongly dependent on the graft territory and the degree of sten-
osis of the native coronary. The best results with the radial artery are
achieved in high-grade stenosis (.90%), when the graft is harvested
as a pedicle, when pharmacological dilatation is applied locally and
when postoperative administration of vasodilator therapy is per-
formed.105–107
Contemporary data on international use of grafts are available
from the SYNTAX trial that included 1541 patients who underwent
CABGat85 sites in 18 countries between2005 and2007.108 In 95.2%
of patients, an arterial graft was anastomosed to the LAD, and in
97.1% at least one arterial graft was used. Bilateral IMA grafting was
only performed in 22.7%. Complete arterial revascularization was
performed in 15.6%. Abdominal arteries were not used at all, and
the radial artery was used in 12.8% of patients.
Invasiveness
Since its introduction, CABG has been performed with and, to a
lesser degree, withoutCPB, even though on-pumpCABG is referred
to ‘conventional CABG’. The use of CPB and cardioplegic arrest pro-
vides a more stable and bloodless operative field, but are associated
with a systematic inflammatory response, increased red cell damage
and stroke frommanipulation and clamping of the ascending aorta.109
With the development of heparin-coated circuits in 1983,110
CPB-associated systemic inflammation became less of an issue.
Off-pump CABG (OPCAB) avoids the use of CPB altogether and, if
performed in a no-touch technique, by avoiding aortic manipulation
has the potential to reduce the risk of stroke. The benefit of OPCAB
is, however, offset by a more challenging technical demand. Surgical
series from the early 1980s reported excellent results,111,112 which
encouraged further implementation. The introduction of the
Octopus stabilizer in 1996 marked a significant improvement in the
operative technique and reduced the technical difficulty.113 Further-
more, the use of distal anastomotic connector devices was investi-
gated already in 1979 but interest was renewed with the advent of
off-pump procedures, as it would omit difficult suturing on a
beating heart.114 Series reporting increased rates of repeat revascu-
larization have hampered widespread use of distal connector
devices,115 although recent favourable results have been reported
as well.116 Off-pump coronary artery bypass grafting is performed
particularly in developing countries to reduce the procedural costs.
However, numerous large randomized trials have not proven an
early or long-term clinical advantage ,and there appears to be no
benefit of off-pump CABG with respect to quality of life.117–120
In 1994, a number of centres were performing LIMA-to-LAD min-
imally invasive CABG (MIDCAB) through a left mini thoracotomy
using video-assisted LIMA harvesting.121,122 Growing experiences
have shown excellent results for the LIMA to LAD similar to CABG
through a sternotomy. Reported early patency rates range from 94
to 99% and perioperative mortality is 0.8% for the largest
series.123,124 Survival at 5 and 7 years for all-comers populations are
reported as 91.9% (95% CI 90.1–93.8%) and 89.4% (95% CI 86.7–
92.1%), respectively.123 Familiarity with video-assisted procedures
furthermore reduced surgical trauma through robotic-assisted
totally endoscopic CABG.125 Initially, it was performed on-pump
and patency results were inferior compared with those achieved
with the standard MIDCAB technique; more recent results with
advanced computer-assisted technology, better endoscopic stabili-
zers, and without the use of CPB have shown excellent results with
up to 100% LIMA to LAD patency and very low conversion rates.126
The patient population
Disease specifics
The principal indication for CABG utilization was (chronic) stable
angina,41 whether by single-, double,- or three-vessel disease. The
benefit of revascularization became more evident in patients with
complex coronary disease as outcomes with medical therapy grad-
ually worsened with increasing complexity, while outcomes after
CABG were consistent.41 In patients with left main disease the
benefit of CABG was largest.
For many years CABG was the only revascularization strategy
proven to be effective and has therefore been used for a number of
clinical scenarios. In the 1960s and 1970s, patients with acute MI
often did not survive to reach the hospital or died early thereafter.127
Acute MI was therefore considered a contraindication for CABG.128
In very selected cases, emergency CABG was performed and did
show increasingly improved results when compared with medical
therapy.129 However, with the advent of fibrinolysis and PCI to
acutely treat the culprit lesion,130,131 early survival of patients with
acute MI significantly improved. Since the early 1990s, PCI has been
the treatment of choice while the need for CABG has been limited
to a minority of acute MI cases with a disease pattern too complex
for PCI. Patients requiring additional bypasses for non-culprit
lesions do undergo subsequent elective CABG.
In the initial CABG trials, patients with severe left ventricular (LV)
dysfunction were excluded. However, the dismal prognosis of such
patients treatedmedically led to explore the impact ofCABGon long-
term survival in patients with severe LV dysfunction. A prognostic
benefit was first confirmed by registry data.132,133 Utilization of
CABG forLVdysfunction subsequently increasedbutwas limitedprin-
cipally to patients who would suffer from angina, with limited hypoki-
nesia and with an expected improvement of ventricular function.
Interestingly, the impact of CABG on improving LV dysfunction in
patients with ischaemic heart failure has not been adequately
addressed over the years and continues to remain under debate.134
Guideline recommendations are similar to what they were half a
century ago, although recent results from the randomized STICH
trial shed new light on this discussion: in the intention-to-treat analysis
there was no difference in the primary endpoint of all-cause mortality
at 5-year follow-up (41 vs. 36% for medical therapy and CABG, re-
spectively; P ¼ 0.12).135 CABG was associated with significantly
reduced rates of the secondary endpoint of all-causemortality or hos-
pitalization (HR ¼ 0.81, 95% CI 0.71–0.93; P ¼ 0.003). Moreover, a
per-protocol analysis excluding crossed-over patients showed that
CABGwas superior to medical therapy also for the primary endpoint
(HR ¼ 0.76, 95% CI 0.62–0.92; P ¼ 0.005). It is crucial to assess the
percentage of myocardial ischaemia as a trigger for revascularization,
with a proposed cut-off of 12% ischaemia.136
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Patient specifics
The early populations that underwent CABG included patients at
a mean age of 50–55 years, the majority were males, smoking
history was frequent28,41,137,138 and diabetes and hypertension
were present in 10–30 and 20–50%, respectively.138,139 Evalu-
ation of patient subgroups who underwent coronary angiography
demonstrated that male patients were more likely to undergo
CABG than women and Caucasians more than blacks.140 As
expected from theworseningWestern lifestyle that involves less ex-
ercise, amplified dietary intake, more stress and sleep deprivation,
patients referred for CABG are becoming increasingly higher risk.
Over the last two decades, the mean age of patients undergoing
CABG has increased to about 60–65 years of age.141,142 An ever in-
creasing number of patients present with co-morbidities; between
2000and2009 in theUSA,e.g. the rateofdiabetes in theCABGpopu-
lation has grown from 33 to 40%, hypercholesterolemia from 60 to
84% andCOPD from17 to 23%.Other risk factors such as hyperten-
sion, renal failure requiring dialysis, previous stroke and prior PCI all
have increased in prevalence.141 Interestingly, it appears that CABG
remains underutilized in black patients as well as in women.143
In those patients requiring revascularization, the trendof thefirst 50
years has led to utilization of CABG particularly in patients with stable
angina, complex CAD, not too high risk and with an expected long-
term benefit for IMA grafts.144–146 Patients with concomitantmoder-
ate/severe aortic stenosis ormitral valve regurgitation require surgical
intervention according to the current guidelines. However, advance-
ments in percutaneous valvular therapies (transcatheter aortic147,148
andmitralvalve149 techniques)mayallowan increasingnumberofhigh-
risk patients tobe treated percutaneously by theHeart Teamand con-
sequently undergo PCI for concomitant CAD.150
Postoperative clinical outcomes
Outcomes
The periprocedural risk of elective CABG has constantly declined
despite an ageing population. Owing to the invasiveness of CABG,
several procedural risks require consideration (Table 1). Mortality
is considered operation-related if it occurs within 30 days after
surgery. Even though the patient population is becoming older and
of higher operative risk,193 mortality continues to decline in contem-
porary practice; currently, operativemortality forelectiveCABG is in
the range of 1–3%. One of the most devastating complications is
stroke.194 Approximately 1–3%of patients suffer an intraprocedural
or early postoperative stroke, which are predominantly ischaemic in
nature.195,196 Other important complications are postoperative MI
or injury, renal failure, delirium, deep sternal wound infection,
mediastinitis and atrial fibrillation. Re-exploration for bleeding is
required in 2–6% of patients and increases the risk for these
complications.163,164
Complications are associated with increased morbidity, longer
postoperative stays, higher costs, and increase the risk of early or
delayedmortality. The risk may be reduced by adopting (and consid-
ering early in the decision-making process) lesser-invasive surgical
techniques and/or by applying intraoperative quality assessments.197
Determinants of short-term outcomes
Many of the procedural complications associated with CABG can be
anticipated on the basis of the preoperative patient history, charac-
teristics and demographics.198 These factors can be divided into
the categories of: factors with an impact on howwell a patient toler-
ates the invasiveness of CABG (e.g. age, COPD, renal function),
factors that identify the progression of disease (e.g. acute coronary
syndrome, left ventricular function, NYHA and CCS classification),
factors that impact procedural complexity (e.g. previous surgery,
emergent surgery, the presence of acute ischaemic mitral regurgita-
tion), and factors that influencepostoperative recovery (e.g. diabetes,
neurological impairment, reduced mobility). To provide an estimate
of the operative risk based on these factors, several generic risk
models have been developed.199–202 These can be helpful tools
during decision making;203 in some instances, it may be more appro-
priate to referpatients to the interventional cardiologist for PCI145 or
continue with medical therapy only. The additive and logistic Euro-
SCORE have been used most frequently in Europe,200,204 and have
recently been updated to the EuroSCORE II (Figure 5A).205 The
Society of Thoracic Surgeons (STS) score is the standard risk
model in the USA and its popularity is increasingly recognized in
Europe as well (Figure 5B).151,201 The existing risk models have
been severely criticized over the recent years for a number of
reasons,198,206–208 including (i) models have become outdated
because of dynamic trends in patient risk, (ii) (lack of) inclusion of
risk factors, (iii) the majority of models have been developed to
predict mortality but do not predict postoperative complications
(e.g. stroke) and (iv) suboptimal methodology for model develop-
ment. Therefore, risk estimation by such models should not be
taken as gospel, but rather used as guidance and interpreted accord-
ing to the individual patient.
Notonly patient-related factors areessential in this regard. A great
number of studies have been devoted to assess volume–mortality
interactions, where the number of cases per surgeon and/or hospital
influences CABG outcomes. As one would expect, the expertise of
higher-volume surgeonswould bebeneficial to the qualityof thepro-
cedure, particularly in complex and/or critical situations. Similarly,
the quality of perioperative care in high-volume centres would
likely be improved when compared with low-volume centres,
thereby reducing the risk of adverse events. Although these assump-
tions have shown to be genuine in several large studies,209,210 results
have been challenged.211–213 Compared with other major complex
surgeries, the impact of volume on outcomes after CABG is
limited.214 More important than volume itself are quality measures
and being a low-volume centreby itself does not necessarily preclude
quality.214–216 Other factors independent of the patient, operator,
and/or hospital, have also shown to impact postoperative complica-
tions; for example the duration of red-cell storage in patients requir-
ing blood transfusions.217
Long-term clinical outcomes
Outcomes
In the early randomized trials (patient inclusion 1972–1984) compar-
ingCABGwithmedical therapy, long-term survival at 5 and 10 years of
follow-up was 90 and 74%, respectively.41 Remarkably, in later trials
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Table 1 Incidence and predictors of early clinical outcomes after coronary artery bypass surgery, with a focus on perioperative considerations to prevent
complications
Complication Incidence Specific predictors Outcome Considerations References
Mortality 1–3% Awide variety of predictors of mortality have been
identified. These are generally factors that are
associated with how well the patient tolerates
the procedure, the progression of disease, the
procedural complexity, and the postoperative
recovery.
N/A Reduce procedural invasiveness and adequately
select patients for CABG by implementing
multidisciplinary Heart Team meetings.
119,151–153
Stroke 1–3% Historyof cerebrovascular disease, atrial fibrillation,
peripheral vascular disease, hypertension, and
severe atherosclerotic aorta.
Postoperative stroke has been found to increase the
risk of 30-day mortality by five- to six-fold.154,155
In an analysis of 469 444 patient-years of follow-up,
long-term survival after 20 years was significantly
reduced (12 vs. 35%, P, 0.001) even after
propensity-matching (22 vs. 35%, P, 0.001).154
Off-pump CABG or anaortic surgery, and
epiaortic scanning are measures that are
associated with reduced rates of stroke in
(selected) patients.
119,151–156
Myocardial
infarction
2–10% Causes include, although are not limited to,
insufficient myocardial protection, air embolism,
and regional and/or global ischaemia during the
procedure.
Other predictors are: urgency of procedure,
recent MI, number of distal anastomoses,
incomplete revascularization, longer
cardiopulmonary bypass time.
Myocardial injury, as measured by CK-MB levels
within 24 h after surgery, was the strongest
predictor of 30-day mortality even after
correction for baseline risk in a pooled analysis of
7 CABG trials that included.18 000 patients.157
Sufficient myocardial protection should be used,
which includes cardioplegia and thermal
regulation.
Operative graft flow measurement may identify
grafts that need revision.
119,152,158–162
Re-exploration
for bleeding
2–6% Body surface area or body mass index, urgency of
operation, preoperative antiplatelet and/or
anticoagulation use, complexity of coronary
disease or number of distal grafts, previous
cardiovascular interventions,
immunosuppressive therapy, preoperative
cardiogenic shock.
Re-exploration for bleeding increases the risk of
stroke, MI, pneumonia, and deep sternal wound
infection, but also significantly increases theuseof
blood products and prolongs postoperative
hospital stay by about 2 days.163,164
Discontinuation of anti-platelet and/or
anticoagulation therapy before surgery is
crucial.
Antifibrinolytic agents may reduce blood loss.
The reduction in operative time should be
weighed against increased rates of
re-exploration.
119,162–166
Delirium 10–50% Older age, preoperative renal function, cognitive
function, prior cerebrovascular disease, duration
of cardiopulmonary bypass.
Delirium is associated with increased morbidity and
mortality, as well as prolonged hospital stay and
increased hospitalization costs.
A multicomponent intervention for the
management of cognitive impairment, sleep
deprivation, immobility, visual and hearing
impairment, and dehydration reduces number
and duration of delirium episodes.167
168–173
Renal failure
(requiring
dialysis)
Highly variable
depending
on the
definition:
5–50% (1%
requires
dialysis)
Preoperative renal function, diabetes, preoperative
cardiogenic shock.
Renal failure is a significant predictor of short- and
long-term mortality, even in patients with
preoperative normal renal functions.174,175
Off-pump surgery has been found to reduce the
rate of renal failure.
Easy preventive strategies consist of:
preoperative hydration, prevention and
correction of hypotension, abandon the use of
nephrotoxic drugs, and use of nonionic
contrast during angiography.176
119,177,178
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comparing CABGwith PCI, the long-term survival did not significantly
improve. The BARI trial included 1829 patients through 1988–1991
and reported 5- and 10-year survival rates nearly identical to earlier
trials: 89 and 74%, respectively.62 The most recent 5-year follow-up
data originates from the SYNTAX and FREEDOM trials.65,195 Again,
survival was similar with 89% in SYNTAX and 89% in FREEDOM. It
should, however, be noted that these trials included patients with
impaired LV function and either complex leftmain and/or three-vessel
disease (SYNTAX), or diabetics with complex disease (83% three-
vessel disease, FREEDOM); compared with the first randomized
trials where only 50% had three-vessel disease, impaired LV function
was an exclusion criteria and patients were generally lower risk.41 In
large registries that include ‘real-world’ ‘all-comers’ data, 5-year
survival has been estimated at 78–82%.66 ,218,219 To summarize, it
appears as if the improvements in patient care (pre-, operative, and
post-operative) have kept an even pace with the increase in patient
morbidity, resulting in similar rates of survival today as in previous
years with lower risk patients.
Data from the PREVENT IV trial showed that the rate of SVG
failure was a dramatic 25% at 1 year.220 The high graft failure rate
was associated with an increased risk of MI during follow-up, which
in turn is associatedwith increasedmortality, left ventricular dysfunc-
tion and reduced quality of life. In a pooled analysis of four rando-
mized trials by Daemen et al., the risk of non-fatal MI at 5 years
after CABG was 7.6%.64 Even though SYNTAX and FREEDOM
included more complex patients, the rates of MI were somewhat
lower (3.8 and 6.0%, respectively), suggesting a continuous improve-
ment in long-termoutcomes afterCABG. The occurrence ofMImay
require repeat revascularization; however, caution is advised when
interpreting repeat revascularization rates because the decision to
treat is a less well-defined, subjective endpoint.
After the perioperative phase, the risk of stroke after CABG
remains constant at approximately 0.5–0.8% per year.154 At 5-year
follow-up, the rate of stroke is 2.5–5%.65,195,221,222 Longest follow-
up is available from the MASS II trial, where the 10-year stroke rate
was 8.4%.223 These data are consistent with a limited number of pro-
spective observational studies.224,225 There is little evidence regard-
ing the severity of strokes, but results from the FREEDOM trial
suggest that strokes were severely disabling in 55% of diabetic
patients with a stroke at any time during follow-up.195 In addition,
results from the SYNTAX trial show that 68% of patients who suf-
fered a stroke and survived had long-term residual deficits.196
Several observational studies226,227 and randomized studies have
shown that health-related quality of life is significantly improved
with CABG. At 3months after randomization in the VACooperative
Study, subjective improvement was reported in 79.8% of patients
who underwent CABG compared with only 58% of the medically
managed patients (P, 0.01).228 At longer follow-up of 5 years, it
was found that more patients in the CABG group were free from
chest pain (54.8% vs. 32.9%; P, 0.01). Data from the CASS trial
support these findings, but showed that differences in freedom
from angina and the activity level between surgery and medical
therapywere less by 10-year follow-up because late surgerywas per-
formed in almost 40% of patients randomized to medical therapy.43
With regard to psychobehavioural endpoints, specific attention has
been given to depression during the perioperative period and long-
term follow-up after CABG. Up to 47% of patients present with
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depression at baseline, which has a significant impact on long-term
freedom from cardiovascular events and death.229–231
Determinants of long-term outcomes
There are a number of factors that have a significant impact on long-
termoutcomes. Postoperative complications such as stroke,156 renal
failure,174 atrial fibrillation,186 and myocardial injury232 diminish
patient survival as well as quality of life. Procedural factors including
graft patency and completeness of revascularization are critical to
ensure reduction in angina pectoris and preservation of the left ven-
tricle. The degree of periprocedural blood loss as measured by the
need for (and number of) red blood cell transfusions has been
found to be an independent predictor of long-term survival.233 Fur-
thermore, life expectancy is significantly reduced by non-coronary
disease patient-related factors such as advanced age, the presence
of co-morbidities and pshychobavioral deficits. Finally, life-long
optimal medical therapy and other secondary prevention measures
after CABG positively impact the incidence of late events after
CABG, although secondary prevention including antiplatelet
therapy has been underused after CABG.
The choiceof graft is oneof themost important procedural factors
to consider. Grafting the LIMA to the LAD undoubtedly is the best
treatment option to prolong survival,85 but there are several grafts
that can be used for other myocardial territories: the SVG, the
right IMA and the radial artery. Bilateral IMA grafting with the left
and right IMA produces the best long-term survival,234 but may not
always be feasible and/or safe; it increases the risk of sternal wound
complications particularly in obese and diabetic patients. Recent evi-
dence suggests that under such circumstances the radial artery pro-
vides better long-term patency and survival than the SVG.105,235–239
Complete revascularization is usually the goal of CABG, as incom-
plete revascularization may be associated with reduced survival
during follow-up. However, results are not uniform; there is a differ-
ence in appropriateness of incomplete revascularization.240 Where
incomplete revascularization of distal lesions and/or small vessels
with little myocardium at risk may be categorized as appropriate in-
complete revascularization,241 leaving a large area of viable myocar-
dium in patients with more complex disease would result in
inappropriate incomplete revascularization and subsequently lead
to detrimental outcomes.
Procedure-specific risk models have been developed to predict
long-term mortality based on preoperative patient characteris-
tics.218,242–244 Naturally, the procedural and post-procedural
factors as discussedearlierwill havea significant impact, but recogniz-
ing the impact of preoperative risk factorsmay be helpful in assessing
the risk–benefit ratio of surgical revascularization. It is advised to use
these during multidisciplinary Heart Team decision-making. Clearly,
the life expectancy of older patients or patients with severe co-
morbidities is limited, and CABG with several months of rehabilita-
tion may not be the best treatment recommendation.
Conclusions
Surgical treatment for CAD has shown substantial improvements
that finally led to the introduction of CABG. During the first 50
years of performing CABG, the technique has evolved into a
refined, safe, andefficientprocedure thateven in contemporaryprac-
tice shows a continuous reduction in postoperative complications. It
has been an extensively investigated topic that has accumulated a
body of evidence in favour of performing CABG for a wide range
of clinical scenarios, and provided crucial data that is weighted
during decision making and can be integrated in risk–benefit ratios
to optimize treatment recommendations. However, there are still
a number of procedural advancements that may be considered to
improve short- and long-term outcomes. In an accompanying manu-
script, we discuss inmore detail off-pumpCABG, clampless/anaortic
CABG,minimally invasiveCABGwithorwithout extending tohybrid
procedures, arterial revascularization, endoscopic vein harvesting,
intraprocedural epiaortic scanning, graft flow assessment, and
improved secondary prevention measures.
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